Literature DB >> 24139470

Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma.

H A Borja-Consigliere1, A López-Pestaña2, M J Vidal-Manceñido3, A Tuneu-Valls2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24139470     DOI： 10.1016/j.ad.2013.07.007

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN： 0001-7310


× No keyword cloud information.
  6 in total

1.  Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial.

Authors:  John A Zic; Brittany T Straka; Laura Y McGirt; Hui Nian; Chang Yu; Nancy J Brown
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

2.  Neurokinin 1 Receptor Antagonists for Pruritus.

Authors:  Majid Alam; Joerg Buddenkotte; Fareed Ahmad; Martin Steinhoff
Journal:  Drugs       Date:  2021-03-06       Impact factor: 9.546

3.  Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.

Authors:  Johanna S Song; Marianne Tawa; Nicole G Chau; Thomas S Kupper; Nicole R LeBoeuf
Journal:  BMC Cancer       Date:  2017-03-16       Impact factor: 4.430

Review 4.  NK-1 Receptor Antagonists and Pruritus: Review of Current Literature.

Authors:  Marcelina Pojawa-Gołąb; Kamila Jaworecka; Adam Reich
Journal:  Dermatol Ther (Heidelb)       Date:  2019-06-12

5.  Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.

Authors:  Bruno Vincenzi; Mike Trower; Ajay Duggal; Pamela Guglielmini; Peter Harris; David Jackson; Mario E Lacouture; Emiliangelo Ratti; Giuseppe Tonini; Andrew Wood; Sonja Ständer
Journal:  BMJ Open       Date:  2020-02-06       Impact factor: 2.692

6.  Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP.

Authors:  C Le Gall-Ianotto; R Verdet; E Nowak; L Le Roux; A Gasse; A Fiedler; D Carlhant-Kowalski; P Marcorelles; L Misery; J C Ianotto
Journal:  Trials       Date:  2021-12-19       Impact factor: 2.279
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.